New nanomedicine aims to treat cognitive disorders in HIV patients.
LAUR-201 (V-Smart®-TNV for Neuro-HIV): Novel V-Smart® Nanomedicine for Treatment of HAND
This study is testing a new treatment called LAUR-201 that helps deliver an HIV medication, Tenofovir, more effectively to the brain, which could help improve thinking and memory problems that some people with HIV experience.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lauren Sciences, LLC NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10544378 on NIH RePORTER |
What this research studies
This research focuses on developing a novel nanomedicine called LAUR-201, designed to improve the delivery of Tenofovir, a common HIV medication, to the brain. Many HIV patients experience neurocognitive disorders despite treatment, as current therapies do not effectively penetrate the blood-brain barrier. By utilizing advanced nanotechnology, this approach aims to enhance the therapeutic effects of Tenofovir in the central nervous system, potentially alleviating cognitive deficits associated with HIV. Patients participating in this research may receive a treatment that targets the underlying issues of HAND more effectively than existing options.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-positive individuals experiencing neurocognitive disorders despite being on antiretroviral therapy.
Not a fit: Patients who are not HIV-positive or those without cognitive impairments related to HIV are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for HIV patients suffering from cognitive disorders, significantly improving their quality of life.
How similar studies have performed: While the approach of using nanomedicine for drug delivery is gaining traction, this specific application for treating HAND with Tenofovir is novel and has not been extensively tested in prior studies.
Where this research is happening
New York, United States
- Lauren Sciences, LLC — New York, United States (Active)
Researchers
- Principal investigator: Rosenbaum, Susan K — Lauren Sciences, LLC
- Study coordinator: Rosenbaum, Susan K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.